No abstract

Galanthamine is a third‐generation cholinesterase inhibitor used against Alzheimer's disease. New analytical methods for the determination of galanthamine in pharmaceutical preparatives and biological fluids, such as urine and serum, were developed. An experimental design and artificial neural network approach were used for method optimization. Thirty‐five ppb of galanthamine were determined in serum samples (with addition of 10 mM magnesium chloride and using solid‐phase preconcentration).

No abstract

No abstract

No abstract